Magee Thomson Investment Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Magee Thomson Investment Partners’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1K	Buy	+46	New	+$725	﹤0.01%	72

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Magee Thomson Investment Partners's PRTK Position: Q1 2017 in Review

Magee Thomson Investment Partners opened a new position in Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2017: 46 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #72 among its holdings.

103 funds tracked by Wall St. Rank hold PRTK as of Q1 2017.

Magee Thomson Investment Partners held 46 shares of Paratek Pharmaceuticals, Inc. worth $1K as of Q1 2017.
Paratek Pharmaceuticals, Inc. was a new Magee Thomson Investment Partners position in Q1 2017.
Paratek Pharmaceuticals, Inc. made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #72 holding.
103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.